151 related articles for article (PubMed ID: 21955862)
1. ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial.
Titan SM; M Vieira J; Dominguez WV; Barros RT; Zatz R
Clin Nephrol; 2011 Oct; 76(4):273-83. PubMed ID: 21955862
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic resistance to ACEI and ARB combination in macroalbuminuric diabetic nephropathy.
Futrakul N; Futrakul P
Clin Nephrol; 2012 Sep; 78(3):250. PubMed ID: 22541688
[No Abstract] [Full Text] [Related]
3. Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin II receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
Esteghamati A; Noshad S; Jarrah S; Mousavizadeh M; Khoee SH; Nakhjavani M
Nephrol Dial Transplant; 2013 Nov; 28(11):2823-33. PubMed ID: 24009294
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis: the efficacy and safety of combined treatment with ARB and ACEI on diabetic nephropathy.
Ren F; Tang L; Cai Y; Yuan X; Huang W; Luo L; Zhou J; Zheng Y
Ren Fail; 2015 May; 37(4):548-61. PubMed ID: 25707526
[TBL] [Abstract][Full Text] [Related]
5. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes.
Cetinkaya R; Odabas AR; Selcuk Y
Int J Clin Pract; 2004 May; 58(5):432-5. PubMed ID: 15206496
[TBL] [Abstract][Full Text] [Related]
6. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
[TBL] [Abstract][Full Text] [Related]
7. Renal Protective Effects of Combination of Diltiazem and ACEI/ARB on the Progression of Diabetic Nephropathy: Randomized Controlled Trial.
Krairittichai U; Sarinnapakorn V; Mahannopkul R; Ainwan P
J Med Assoc Thai; 2017 Feb; 100 Suppl 1():S40-7. PubMed ID: 29927180
[TBL] [Abstract][Full Text] [Related]
8. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
Tylicki L; Rutkowski P; Renke M; Rutkowski B
Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
[TBL] [Abstract][Full Text] [Related]
9. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy.
Kuriyama S; Tomonari H; Abe A; Imasawa T; Hosoya T
Nephron; 2000 Dec; 86(4):529-30. PubMed ID: 11124615
[No Abstract] [Full Text] [Related]
11. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
[TBL] [Abstract][Full Text] [Related]
12. Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy.
Tan F; Mukherjee JJ; Lee KO; Lim P; Liew CF
Singapore Med J; 2010 Feb; 51(2):151-6. PubMed ID: 20358155
[TBL] [Abstract][Full Text] [Related]
13. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
Renke M; Tylicki L; Rutkowski P; Rutkowski B
Scand J Urol Nephrol; 2004; 38(5):427-33. PubMed ID: 15764256
[TBL] [Abstract][Full Text] [Related]
14. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
Rossing K; Jacobsen P; Pietraszek L; Parving HH
Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
[TBL] [Abstract][Full Text] [Related]
15. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
Pathak JV; Dass EE
Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
[TBL] [Abstract][Full Text] [Related]
17. FGF-23 as a predictor of renal outcome in diabetic nephropathy.
Titan SM; Zatz R; Graciolli FG; dos Reis LM; Barros RT; Jorgetti V; Moysés RM
Clin J Am Soc Nephrol; 2011 Feb; 6(2):241-7. PubMed ID: 20966122
[TBL] [Abstract][Full Text] [Related]
18. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with lamivudine and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker for hepatitis B virus-associated glomerulonephritis with mild to moderate proteinuria: a clinical review of 38 cases.
Sun LJ; Shan JP; Cui RL; Yuan WJ; Jiang GR
Int Urol Nephrol; 2017 Jun; 49(6):1049-1056. PubMed ID: 28283858
[TBL] [Abstract][Full Text] [Related]
20. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
Ferrari P; Marti HP; Pfister M; Frey FJ
J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
